Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc is advancing its innovative cell therapy pipeline, particularly with its CoStAR platform, showcasing significant potential in targeting various solid tumors through its ITIL-306 therapy. The company operates within a burgeoning market influenced by promising results in related biopharmaceuticals, highlighted by the recent positive updates from Summit on ivonescimab, which enhances optimism for the broader bispecific class. With the anticipated upcoming data from ongoing trials, Instil Bio stands positioned to benefit from a favorable market environment, supported by advances in oncological treatments that may bolster investor confidence and drive future developments.

Bears say

Instil Bio Inc. faces significant investor skepticism due to the perceived lack of substantial improvement in overall survival (OS) curves following recent updates, which has led to concerns about the efficacy of its clinical pipeline. Challenges such as potential delays in advancing clinical candidates, the risk of generating unfavorable clinical data—especially with pivotal treatments like AXN-2510 for NSCLC and SCLC—and the looming threat of dilution present further headwinds for the company's financial outlook. These cumulative risks contribute to a negative sentiment surrounding Instil Bio's stock, particularly when juxtaposed with its current enterprise value of $136 million.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.